A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Dermatology"
DOI: 10.1684/ejd.2016.2923
Abstract: Nivolumab is a monoclonal antibody directed against PD1 (programmed cell death 1) that can improve survival in patients with metastatic melanoma. Such immune checkpoint inhibitors have been known to induce type 1 diabetes mellitus (T1D)… read more here.
Keywords: fulminant type; type diabetes; diabetes mellitus; case fulminant ... See more keywords